News for Heron Therapeutics, Inc. (HRTX)

On March 4, 2025, TANG KEVIN C (Trades, Portfolio), a recognized market expert, executed a significant stock transaction involving Aurinia Pharmaceuticals Inc (

Net Income (Q4 2024): $3.6 million.Net Revenues (Full Year 2024): $144.2 million, a 14% year-over-year increase.Adjusted EBITDA (Full Year 2024): $8.6 million.

Feb 27, 2025 / 01:00PM GMTOperator Good day and thank you for standing by and welcome to the Heron Therapeutics Q4 2024 conference call. (Operator Instructions)

Heron Therapeutics, Inc. (NASDAQ:HRTX) Q4 2024 Earnings Conference Call February 27, 2025 8:00 AM ETCompany ParticipantsMelissa Jarel - Executive Director,...

Net Income: Achieved Q4 2024 GAAP Net Income of $3.6 million, marking a significant turnaround from the previous year's loss.Quarterly Revenue: Reported Q4 202

PR NewswireCARY, N.C., Feb. 27, 2025 Achieved Q4 2024 GAAP Net Income of $3.6 millionGenerated full-year 2024 Net Revenue of $144.2 million, up 14% year-ov

PR NewswireSAN DIEGO, Dec. 23, 2024 SAN DIEGO, Dec. 23, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commerci

On December 10, 2024, Velan Capital Investment Management LP (Trades, Portfolio) executed a significant transaction involving Protara Therapeutics Inc (TARA). T

Israel-based PainReform Ltd. (PRFX), a clinical stage specialty pharmaceutical company is up over 142 percent in Thursday's pre-market trading. The following are some of the other stocks making big moves in Thursday's pre-market trading.

Heron Therapeutics’ court win strengthens its position for 2025. Find out why HRTX stock shows potential for a recovery despite missed Q3 estimates.

Heron stock surges on win in patent case against Fresenius

Shares of Marvell Technology, Inc. MRVL rose sharply in today's pre-market trading after the company reported better-than-expected third-quarter financial resul...

PR NewswireSAN DIEGO, Dec. 3, 2024 ”” Court Rules in Favor of Heron in Patent Lawsuit Against Fresenius Kabi USA, LLC ””SAN DIEGO, Dec. 3, 2024 /PRNewswi

Heron has characteristics that are associated with high risk investments.

Following underperformance in Q2 2024, the Franklin Biotechnology Discovery Fund returned to strength in Q3 2024. Click here to read the full commentary.

Heron Therapeutics, Inc. (NASDAQ:HRTX) Q3 2024 Earnings Conference Call November 12, 2024 8:00 AM ETCompany ParticipantsMelissa Jarel - Executive...

Net Product Sales: Achieved $32.81 million for Q3 2024, surpassing the previous year's $31.43 million, indicating a positive growth trajectory.Gross Profit: In

Overview of the Recent Transaction On September 30, 2024, Velan Capital Investment Management LP (Trades, Portfolio) executed a significant transaction by acqui

Aug 06, 2024 / 08:30PM GMTOperator Thank you for standing by. My name is Jeremaine, and I will be your conference operator today. At this time, I would like to